Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

AstraZeneca

1,872.00 SEK

-0.61 %

Less than 1K followers

AZN

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-0.61 %
+13.49 %
+9.89 %
+8.40 %
+24.06 %
+15.41 %
+37.95 %
+127.43 %
+10,143.22 %

AstraZeneca is a global pharmaceutical company focused on the research, development and marketing of prescription medicines, primarily for the treatment of diseases in the therapeutic areas of respiratory, cardiovascular/metabolic and cancer. In addition to its core business, the company also has a focus on the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in all global regions and is headquartered in Cambridge, UK.

Read more
Market cap
2.9T SEK
Turnover
420.99M SEK
Revenue
540.24B
EBIT %
23.4 %
P/E
30.84
Dividend yield-%
1.57 %
Revenue and EBIT-%

Revenue B

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
9/4
2026

General meeting '26

29/4
2026

Interim report Q1'26

All
Press releases
ShowingAll content types
Press release2/27/2026, 7:03 AM

AstraZeneca: Strensiq approved for restricted reimbursement in Sweden

AstraZeneca
Press release2/25/2026, 7:01 AM

AstraZeneca: Filing of Annual Report on Form 20-F with the US Securities and Exchange Commission

AstraZeneca
Press release2/24/2026, 11:02 AM

AstraZeneca: Annual Financial Report

AstraZeneca

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/20/2026, 7:39 AM

AstraZeneca: Calquence plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukaemia in the 1st-line setting

AstraZeneca
Press release2/13/2026, 7:06 AM

AstraZeneca: Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for Breztri in patients with uncontrolled asthma published in The Lancet Respiratory Medicine

AstraZeneca
Regulatory press release2/10/2026, 7:00 AM

Resultat för AstraZeneca: Helåret samt fjärde kvartalet 2025

AstraZeneca
Press release2/3/2026, 7:34 AM

AstraZeneca: Datroway granted Priority Review in the US as 1st-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for immunotherapy

AstraZeneca
Press release2/3/2026, 7:08 AM

AstraZeneca: Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus

AstraZeneca
Press release2/2/2026, 7:09 AM

AstraZeneca: Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers

AstraZeneca
Press release2/2/2026, 7:05 AM

AstraZeneca begins trading on the New York Stock Exchange

AstraZeneca
Press release1/30/2026, 7:05 AM

AstraZeneca enhances its weight management portfolio through collaboration agreement with CSPC Pharmaceuticals

AstraZeneca
Press release1/29/2026, 9:57 AM

AstraZeneca plans to invest $15 billion in China through 2030 to pioneer the next-generation of innovative medicines

AstraZeneca
Press release1/20/2026, 7:05 AM

AstraZeneca to complete direct listing of ordinary shares and all US debt securities on the New York Stock Exchange

AstraZeneca
Press release1/8/2026, 7:00 AM

AstraZeneca appoints Joris Silon as Head of Investor Relations

AstraZeneca
Press release1/6/2026, 7:00 AM

AstraZeneca: Saphnelo self-administration TULIP-SC trial demonstrates statistically significant and clinically meaningful reduction in systemic lupus erythematosus disease activity

AstraZeneca
Press release12/22/2025, 7:30 AM

AstraZeneca: Enhertu granted Breakthrough Therapy Designation in the US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer

AstraZeneca
Press release12/22/2025, 7:00 AM

AstraZeneca: Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer

AstraZeneca
Press release12/16/2025, 7:10 AM

AstraZeneca: Saphnelo approved in the EU for subcutaneous self-administration as a new pre-filled pen for systemic lupus erythematosus

AstraZeneca
Press release12/16/2025, 7:07 AM

AstraZeneca: Enhertu plus pertuzumab approved in the US as first new treatment in a decade for the 1st-line treatment of patients with HER2-positive metastatic breast cancer

AstraZeneca
Regulatory press release12/4/2025, 8:22 AM

Finansinspektionen: Flaggningsmeddelande i AstraZeneca PLC

AstraZeneca
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.